RDY · Dr Reddys Laboratories Ltd · Debt
$14.15
+0.40 (+2.91%)
At close · Oct 28
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Market Cap
$11.73B
Shares
833.07M
Volume · Oct 28
4.47M
Avg daily vol (3M)
2.92M
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Borrowings | 2026-03-31 | INR 18,206,000,000 | 20-F filed 2026-05-29 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Current portion of long-term borrowings | 2026-03-31 | USD 64,000,000 | 20-F filed 2026-05-29 |
| Lease liabilities | 2026-03-31 | INR 5,436,000,000 | 20-F filed 2026-05-29 |
| Noncurrent long-term borrowings | 2026-03-31 | USD 130,000,000 | 20-F filed 2026-05-29 |
| Short-term borrowings | 2026-03-31 | USD 630,000,000 | 20-F filed 2026-05-29 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Key facts
CIK
1135951
CUSIP
256135203
13F (30d)
56 filings
51 filers
Visit website
Investor relations